1. Luan F, Xu S, Chen K, et al. Prognostic effect of CEA, AFP, CA19 9 and CA242 for recurrence/metastasis of gastric cancer following radical gastrectomy. Mol Clin Oncol. 2024;22(2):17. doi:10.3892/mco.2024.2812
2. Qiu X, Shen C, Zhao W, et al. Prognostic value of the combination of HB (hemoglobin) and CEA in resectable gastric cancer. J Cancer. 2022;13(7): 2246-2257. doi:10.7150/jca.67600
3. Aksoy A. Mide karsinomunda prediktif faktörler. Genel Tıp Derg. 2016; 26(1):1-7. doi:10.15321/GenelTipDer.20162618129
4. Bozan MB, Kanat BH, Yazar FM, et al. Mide kanseri hastalarında preoperatif CEA, AFP ve CA-19.9 düzeylerinin değerlendirilmesi. KSÜ Tıp Fakültesi Derg. 2015;10(3):132-115. doi:10.17576/ksutfd.2015.10. 3. 132115
5. Shibata C, Nakano T, Yasumoto A, et al. Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer. BMC Surg. 2022;22(1):213. doi:10.1186/s12893-022-01667-z
6. Li J, Zhao H, Zhang Q, Ren S. Combined albumin and CEA improve prognostic prediction in resectable gastric cancer. Sci Rep. 2025;15(1): 33118. doi:10.1038/s41598-025-18102-x
7. Bayrak M, Ölmez ÖF, Kurt E, et al. The relationship between pre-treatment serum levels of AFP, CEA and CA 19-9 and clinicopathological factors in patients with locally advanced and metastatic gastric cancer. Uludağ Tıp Derg. 2011;37(3):139-143.
8. Clavien PA, Barkun J, Dindo D, et al. The Clavien-Dindo classification of surgical complications five-year experience. Ann Surg. 2009;250(2):187-196. doi:10.1097/SLA.0b013e3181b13ca2
9. Duraker N, Celik AN. The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001;76(4):266-271. doi:10.1002/jso.1044
10. Kim DY, Kim HR, Shim JH, et al. Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J Surg Oncol. 2000;74(3):185-192. doi:10.1002/1096-9098 (200007)74:3<185::aid-jso4>3.0.co;2-0
11. Zhou YC, Zhao HJ, Shen LZ. Preoperative serum CEA and CA19-9 in gastric cancer--a single tertiary hospital study of 1,075 cases. Asian Pac J Cancer Prev. 2015;16(7):2685-2691. doi:10.7314/apjcp.2015.16.7.2685
12. Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17(1):26-33. doi:10.1007/s10120-013-0259-5
13. Quan Y, Huang A, Ye M, et al. Comparison of laparoscopic versus open gastrectomy for advanced gastric cancer: an updated meta-analysis. Gastric Cancer. 2016;19(3):939-950. doi:10.1007/s10120-015-0516-x
14. Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9 - tumor marker: past, present, and future. World J Gastrointest Surg. 2020;12(12):468-490. doi:10.4240/wjgs.v12.i12.468
15. Suenaga Y, Kanda M, Ito S, et al. Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer. World J Gastrointest Oncol. 2019;11(1):17-27. doi:10.4251/wjgo.v11.i1.17
16. Barman A, Jenny N, Iffat T, et al. Assess the clinical significance of serum CEA and CA 19-9 in patient with gastric cancer. Sch J App Med Sci. 2021;9(6):1083-1092. doi:10.36347/sjams.2021.v09i06.043
17. Yu Z, Liang C, Xu Q, et al. Analysis of postoperative complications and long term survival following radical gastrectomy for patients with gastric cancer. Sci Rep. 2024;14(1):23869. doi:10.1038/s41598-024-74758-x